Article

D. Ross Camidge on the Development of a New Lung Cancer Drug

Author(s):

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).

Camidge presented results from a study of brigatinib during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.